EXECUTIVE SUMMARY
The MedTech sector, which found itself in a dilemma between the growth and value rotation throughout 2022, has experienced a significant upswing in 2023. In the midst of persistent inflation concerns in major markets and worrisome consumption patterns fueling fears of a recession, the recent rebound might indicate that quick investors are seeking refuge in the sector's reliable defensive qualities. What is our perspective on the sector's momentum? And how do valuations factor into this equation?
